Warning Letter — VasoCorp, Inc.
The FDA issued a Warning Letter to VasoCorp, Inc. on July 9, 2026, following an evaluation under the Human Foods Program. The specific nature of the violations is not detailed in the provided excerpt beyond the issuance of the letter.
This affects VasoCorp, Inc., their regulatory affairs and quality assurance departments, and potentially other entities operating under the Human Foods Program with similar product profiles.
Warning Letters from the Human Foods Program typically indicate significant deviations from regulatory requirements, often involving labeling, manufacturing standards, or unapproved claims. This issuance suggests that the firm's current compliance posture is insufficient, posing a risk of further enforcement action such as seizure or injunction if the underlying issues are not remediated.
Regulatory and QA teams should conduct a comprehensive review of all product labeling and marketing materials to ensure no claims transition a food product into the unapproved drug category. Legal and compliance departments should prepare a formal response addressing the specific violations cited in the 07/09/2026 letter.
FDA Warning Letter issued to: VasoCorp, Inc.. 07/09/2026 — Human Foods Program. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/vasocorp-inc-732724-07092026
Open in openFDA / FDA.gov